Osteoporosis Prevention and Treatment: Pharmacological Management and Treatment Implications

Drugs and Aging

Volumn 9, Issue 6, 1996, Pages 472-477

  Sankaran, Shankar K ^a  

^a MIDDLEMORE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; FLUORIDE SODIUM; GROWTH HORMONE; VITAMIN D;

AGED; BONE MASS; COST EFFECTIVENESS ANALYSIS; DIET; DIET SUPPLEMENTATION; DRUG COST; EXERCISE; FRACTURE; HEALTH ECONOMICS; HORMONE SUBSTITUTION; HUMAN; INSTITUTIONAL CARE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SIDE EFFECT;

EID: 0030463795     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199609060-00009     Document Type: Article

References (31)

1. Cummings SR, Kelsey JL, Nevitt MC, et al. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985; 7: 178-208
2. Riggs BL, Melton III LJ. Involutional osteoporosis. N Engl J Med 1986; 314: 1676-86
3. Borg RL, Cassells JS. Osteoporosis. In: Borg RL, Cassells JS, editors. The second fifty years: promoting health and preventing disability. Washington, DC: National Academy Press, 1990: 76-100
4. Cummings SR, Rubin SM, Black D. The future of hip fractures in the United States: numbers, costs and potential effects of postmenopausal oestrogen. Clin Orthop 1990; 252: 163-6
5. Lane A. Direct costs of osteoporosis in New Zealand women. PharmacoEconomics 1996 Mar; 9 (3): 231-45
6. Dempster DW, Lindsay R. Pathogenesis of osteoporosis. Lancet 1993 Mar 27; 341: 797-801
7. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995 Mar 23; 332: 767-73
8. Dalsky GP, Stocke KS, Ensani AA, et al. Weight bearing exercise training and lumbar bone mineral content in postmenopausal women. Ann Intern Med 1988; 108: 824-8
9. Simkin A, Ayalon J, Leichter I. Increased trabecular bone density due to bone-loading exercises in postmenopausal osteoporotic women. Calcif Tissue Int 1987; 40: 59-63
10. Ballamore JR, Gallagher JC, Wilkinson R, et al. Effect of age on calcium absorption. Lancet 1970; II: 535-7
11. Eastell R, Yergey AL, Vieira NE, et al. Interrelationship among vitamin D metabolism, true calcium absorption, parathyroid function and age in women: evidence of an age-related intestinal resistance to 1,25 dihydroxy vitamin D action. J Bone Miner Res 1991; 6: 125-32
12. Riggs BW, Melton JL. Prevention and treatment of osteoporosis. N Engl J Med 1992 Aug 27: 327 (9): 620-7
13. Johnson Jr CC, Miller JZ, Slemenda CW, et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992 Jul; 327 (2): 82-7
14. Chapuy MC, Chapuy P, Meunier PJ. Calcium and vitamin D supplements: effects on calcium metabolism in elderly people. Am J Clin Nutr 1987; 46: 324-8
15. Chapuy MC, Arlot MC, Du Boeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637-42
16. Lufkin EG, Washner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal oestrogen. Ann Intern Med 1992; 117: 1-9
17. Christiansen C, Christinsen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/ gestagen replacement therapy. Lancet 1981; I: 459-61
18. Hodes RJ. Osteoporosis: emerging research strategies aim at bone biology, risk factors, intervention. J Am Geriatr Soc 1995 Jan; 43: 75-7
19. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of oestrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-93
20. Stanford JL, Weiss NS, Voigt LF, et al. Combined oestrogen and progestin hormone replacement therapy in relation to breast cancer in middle-aged women. JAMA 1995; 274: 137-42
21. Storm T, Thamsborg GR, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-71
22. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-9
23. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43
24. Chestnut CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodelling. Am J Med 1995; 99: 144-52
25. Gallagher JC, Riggs BL. Action of 1,25 dihydroxy vitamin D3 on calcium balance and bone turnover and its effect on vertebral fracture rate. Metabolism 1990; 39 Suppl. 1: 30-4
26. Tilyand MW, Spears GFS, Thomson J, et al. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992; 326: 357-62
27. Civitelli R, Gonnelli S, Zacchei F, et al. Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J Clin Invest 1988; 82: 1268-74
28. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802-9
29. Kleerekoper M, Peterson EL, Nelson DA, et al. A randomised trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int 1991; 1: 155-61
30. Pak CY, Sakhace K, Piziak V, et al. Slow-release sodium fluoride in the management of postmenopausal osteoporosis: a randomised controlled trial. Ann Intern Med 1994; 120: 625-32
31. Sogaard CH, Mosekilde L, Richards A. Marked decrease in trabecular bone quality after 5 years of sodium fluoride therapy: assessed by biochemical testing of iliac crest bone biopsies in osteoporotic patients. Bone 1994; 15: 393-9